The globalization of Chinese energy companies

This repository item contains a report from the Boston University Global Economic Governance Initiative. The Global Economic Governance Initiative (GEGI) is a research program of the Center for Finance, Law & Policy, the Frederick S. Pardee Center for the Study of the Longer-Range Future, and the Frederick S. Pardee School of Global Studies. It was founded in 2008 to advance policy-relevant knowledge about governance for financial stability, human development, and the environment

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.

Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC). Although cCRT is potentially curative, 5-year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy. PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC. In addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage III NSCLC. A preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive increase in median progression-free survival with consolidative durvalumab, a PD-L1 inhibitor, compared with observation after cCRT. Here, we discuss the clinical and translational implications of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III NSCLC

Deploying a spreadsheet tool for early economic value assessment of medical device innovations with healthcare decision makers

Early stage evaluation of medical device innovations is important for healthcare decision-makers as much as for manufacturers, meaning that a wider application of a basic cost-effectiveness analysis is becoming necessary outside the usual expert base of health technology assessment specialists. Resulting from an academic-industry-healthcare professional collaboration, a spreadsheet tool is described that was designed to be accessible both to professionals in healthcare delivery organisations and to innovators in the healthcare technology industry who are non-experts in the field of health economics. The tool enables a basic cost-effectiveness analysis to be carried out, using a simplified decision-tree model to compare costs and patient benefit for a new device-related procedure with that of standard care employing an incumbent device or other alternative. Such a tool is useful to healthcare professionals because it enables them to rapidly elucidate the cost-effectiveness of heterogeneous innovations by means of the standard quality adjusted life year (QALY) measure of clinical outcome, which is intended to be broadly comparable across treatments. For the innovator or manufacturer it helps them focus on what is required for future stages of development, in order to fill gaps in the input data and so further strengthen their case from a health economics perspective. Results are presented of first experiences from deploying the tool on three medical device exemplars, in face-to-face meetings of the NHS National Innovation Centre (NIC) along with the innovator or clinical champion. The results show that mapping of device-related innovations to the tool is achievable in a short meeting between the NIC and the innovator using expected costs, outcomes data from the literature and estimates of ranges for unknown input data. Whilst the result of a simplified analysis is not expected to be definitive, the process of reasoning is found to be illuminating for the parties involved, enabling innovators to articulate the benefits of their innovations and for all parties to highlight gaps in data and evidence that will be required to take the innovation forward. The partnership model of the authors’ organisation supports the kind of cooperative design approach that is necessary to produce the kind of tool described.---------------------------7dd39101208fa Content-Disposition: form-data; name="c14_creators_1_name_family" Crave

Quantum Langevin model for exoergic ion-molecule reactions and inelastic processes

We presents a fully quantal version of the Langevin model for the total rate of exoergic ion-molecule reactions or inelastic processes. The model, which is derived from a rigorous multichannel quantum-defect formulation of bimolecular processes, agrees with the classical Langevin model at sufficiently high temperatures. It also gives the first analytic description of ion-molecule reactions and inelastic processes in the ultracold regime where the quantum nature of the relative motion between the reactants becomes important.Comment: 5 pages, 3 figure

Cosmic Mach Number: A Sensitive Probe for the Growth of Structure

In this Letter, we investigate the potential power of the Cosmic Mach Number (CMN), which is the ratio between the mean velocity and the velocity dispersion of galaxies as a function of cosmic scales, to constrain cosmologies. We first measure the CMN from 5 catalogues of galaxy peculiar velocity surveys at low redshift (0.002<z<0.03), and use them to contrast cosmological models. Overall, current data is consistent with the WMAP7 LCDM model. We find that the CMN is highly sensitive to the growth of structure on scales 0.01<k<0.1 h/Mpc in Fourier space. Therefore, modified gravity models, and models with massive neutrinos, in which the structure growth generally deviates from that in the LCDM model in a scale-dependent way, can be well differentiated from the LCDM model using future CMN data.Comment: 7 pages, matches the version accepted to JCA

Realization of random-field dipolar Ising ferromagnetism in a molecular magnet

The longitudinal magnetic susceptibility of single crystals of the molecular magnet Mn$_{12}$-acetate obeys a Curie-Weiss law, indicating a transition to a ferromagnetic phase due to dipolar interactions. With increasing magnetic field applied transverse to the easy axis, the transition temperature decreases considerably more rapidly than predicted by mean field theory to a T=0 quantum critical point. Our results are consistent with an effective Hamiltonian for a random-field Ising ferromagnet in a transverse field, where the randomness is induced by an external field applied to Mn$_{12}$-acetate crystals that are known to have an intrinsic distribution of locally tilted magnetic easy axes.Comment: 4 pages, 4 figure